This article is more than 5 years old. Information may no longer be current.
Alimera reports $5.4 million net loss in third quarter
Click Here to Manage Email Alerts
Alimera Sciences reported a net loss of $5.4 million in the third quarter compared with a net loss of $6.5 million in the same quarter last year, according to a company news release.
The company expects to begin generating revenue in 2013 by marketing Iluvien, a sustained-release intravitreal implant developed by pSivida that delivers sub-microgram levels of fluocinolone acetonide for up to 36 months, in three European Union countries.
“Three commercial batches of Iluvien are expected to be shipped this week to the EU in preparation for the planned commercial launch … starting with Germany in the first quarter of 2013,” Dan Myers, president and CEO of Alimera, said in the release. “We expect to initiate our commercial launch in the United Kingdom during the second quarter of 2013 and in France during the third quarter of 2013.”
For the nine-month period ended Sept. 30, Alimera reported a net loss of $14.5 million, down from $16.4 million in the same period a year ago, according to the release.
Research and development expenses stayed about the same between the third quarter of 2011 and the third quarter of 2012, while marketing expenses fell from $2.6 million to $1.5 million.
Alimera intends to resubmit its new drug application for Iluvien to the U.S. Food and Drug Administration in the first quarter of 2013, the release said.